Related Experiment Video

Updated: Jul 1, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

JunD reduces tumor angiogenesis by protecting cells from oxidative stress

Damien Gerald1, Edurne Berra, Yves M Frapart

  • 1Unit of Gene Expression and Diseases, CNRS URA 1644, Pasteur Institute, 25 Rue du Docteur Roux, 75724 Paris, Cedex 15, France.

Cell
|September 17, 2004
PubMed

Insights

JunD, a transcription factor, inhibits tumor growth by reducing reactive oxygen species (ROS) and limiting blood vessel formation. This study reveals JunD’s role in antioxidant defense and angiogenesis regulation.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cellular Physiology

Background:

  • Reactive oxygen species (ROS) play a critical role in cancer development.
  • Tumor angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis.
  • Transcription factors regulate gene expression involved in cellular processes like oxidative stress and angiogenesis.

Purpose of the Study:

  • To investigate the role of JunD in regulating tumor angiogenesis.
  • To elucidate the molecular mechanisms by which JunD influences reactive oxygen species (ROS) production.
  • To understand how JunD affects the hypoxia-inducible factor (HIF) pathway and its impact on angiogenesis.

Main Methods:

  • Utilized junD-deficient cells to study gene regulation.
  • Assessed the impact of JunD on genes related to antioxidant defense, H2O2 production, and angiogenesis.
  • Analyzed the effects of H2O2 accumulation on FeII availability and HIF prolyl hydroxylase (PHDs) activity.
  • Quantified HIF-alpha protein levels and VEGF-A transcription.

Main Results:

  • JunD deficiency led to increased H2O2 accumulation.
  • Elevated H2O2 reduced PHD activity, causing HIF-alpha accumulation.
  • HIF-alpha accumulation enhanced VEGF-A transcription, promoting angiogenesis.
  • JunD was identified as a regulator of genes involved in oxidative stress and angiogenesis.

Conclusions:

  • JunD exerts an antiangiogenic effect by limiting Ras-mediated ROS production.
  • JunD protects cells from oxidative stress and inhibits tumor angiogenesis.
  • The study reveals a novel mechanism regulating PHD activity and HIF stability in response to oxidative and iron levels.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.